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Abstract | In the past decade, the introduction of molecularly targeted agents and 
immune-checkpoint inhibitors has led to improved survival outcomes for patients with 
advanced-stage lung cancer; however, this disease remains the leading cause of 
cancer-related mortality worldwide. Two large randomized controlled trials of low-
dose computed tomography (LDCT)-based lung cancer screening in high-risk 
populations, NLST and NELSON, have provided evidence of a statistically significant 
mortality benefit in patients.  
LDCT-based screening programmes for individuals at a high risk of lung cancer have 
already been implemented in the USA, and implementation programmes are 
currently underway in the UK following the success of the UKLS trial, which included; 
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the Liverpool Health Lung Project, the Lung Screen Uptake Trial, the West London 
Lung Cancer Screening pilot  and the Yorkshire Lung Screening trial. 
In this Review, we focus on the current evidence on LDCT-based lung cancer 
screening and discuss clinical developments in high-risk populations worldwide; we 
also address aspects such as cost-effectiveness. We present a framework to define 
the scope of future implementation research on lung cancer screening programmes 
referred to as Screening Planning and Implementation RAtionale for Lung cancer 
(SPIRAL). 
 
[H1] Introduction  
 
Lung cancer is currently both the most commonly diagnosed cancer (accounting for 
11.6% of all cancer diagnoses) and the leading cause of cancer-related mortality 
(18.4% of overall cancer mortality) in both men and women worldwide[1]. In the past 
decade, the introduction of molecularly targeted agents and immune-checkpoint 
inhibitors into the therapeutic armamentarium for patients with stage IV (advanced 
stage) lung cancer has led to improved survival outcomes[2]. These therapeutic 
approaches, however, are beneficial only for restricted subsets of patients and, thus, 
the majority of them die within 5 years of lung cancer diagnosis[1]. However, Stage 
1A disease patients have > 75% chance of survival over 5 years[3]. To date, the 
main strategy shown to substantially reduce lung cancer mortality over a longer time 
period is predicated on early detection using low-dose computed tomography 
(LDCT)-based screening in asymptomatic individuals[4–7]. In settings in which lung 
cancer screening programmes have been implemented, annually ~1–3% of 
participants are diagnosed with lung cancer, 50–70% of them with stage I (early 
stage) disease[7–13]. These patients usually undergo surgery with curative intent, 
with other available therapeutic options being stereotactic radiotherapy, 
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brachytherapy and percutaneous tumour ablation. Lung cancer is a tobacco-related 
disease: in high-income countries, ~10–20% of current and former heavy-smokers 
will be diagnosed with lung cancer during their lifetime compared with 1–2% of never-
smokers[14,15]. Thus, individuals with a history of smoking are likely to derive the 
greatest benefit from screening.  
In this Review, we discuss the current evidence supporting the effectiveness of 
implementing national lung cancer screening programmes and also how such 
programmes should be developed in the future. We focus on aspects such as 
identification of the target population, participant recruitment and compliance, 
screening frequency, integrated smoking cessation interventions, cost-effectiveness 
and sex differences. We also present an overview of current lung cancer screening 
programmes worldwide and discuss future opportunities to leverage artificial 
intelligence (AI) in LDCT-based lung cancer screening. All of these areas should be 
considered in the scope of future implementation research programmes on lung 
cancer screening, in a framework we refer to as Screening Planning and 
Implementation RAtionale for Lung cancer (SPIRAL) (FIG. 1). 
  
 
[H1] Identification of a high-risk population  
To minimize potential harms associated with cancer screening (such as exposure to 
radiation) and maximize its effectiveness, screening programmes should be limited to 
individuals who are at high risk of a particular cancer within the general 
population[16]. Typically, screening programmes are focused on a prespecified 
subset of individuals within the general population on the basis of either age (for 
example, in colorectal cancer screening) or a combination of age and sex (such as in 
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breast and cervical cancer screening). For lung cancer screening, an improved 
approach has been implemented in the UK through several lung cancer CT 
screening implementation studies: the Liverpool Healthy Lung project[17], 
Manchester Health lung Check[18], West London Cancer Screening pilot[19] and 
Yorkshire Lung Screening trial[20]. Besides age (>60 years), smoking status has 
been shown to have the greatest influence on the probability of developing lung 
cancer (ie odds ratio for smoking duration 1-19 years compared >60years  2.17 
(1.21–3.85) vs.  15.25 (5.71–40.65 [21]. However, several other factors also 
contribute to this risk, including family history of lung cancer (especially for individuals 
aged <60 years ie odds ratio for early onset compared to late onset ;  2.02 (1.18–
3.45); 1.18 (0.79–1.76[21])) and individual history of other respiratory diseases, other 
malignancies and exposure to asbestos. Other risk factors have been reported in the 
literature, including exposure to radon and a number of other carcinogens (such as 
diesel exhaust fumes), but to date they have not been included in any of the 
validated risk models.  
The use of prediction models integrating several risk factors in lung cancer-screening 
research has gained credence over the past 10 years. Indeed, the use of validated 
risk models is integral to all current screening and early detection programmes in 
Europe. Several multivariable risk prediction models have been published and 
reviewed recently [22]; however, only two — PLCOM2012[23] and LLPv2[24] — have 
thus far been used to guide the selection of participants in lung cancer screening 
clinical trials and projects. In the US National Lung Screening Trial (NLST), current 
and former heavy-smokers (current smokers; 30 or more pack-years of cigarette 
smoking history; former smokers: quit smoking within the previous 15 years). 
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aged 55–74 years were randomly allocated to undergo three annual rounds of 
screening with chest LDCT or single-view chest radiography[4]. The NLST dataset 
has been analysed using several risk-prediction models, leading to the conclusion 
that the NLST selection criteria and the United States Preventive Services Taskforce 
(USPSTF) criteria recommendations for lung cancer screening could have been 
greatly improved if a risk model incorporating variables beyond age and smoking 
history had been implemented[25–27].  
 
Currently, LLPv2 is the only risk model that has been used to select participants in a 
randomized controlled trial (RCT) of lung cancer screening: in the UK lung cancer 
screening (UKLS) trial[28], a 5-year lung cancer risk ≥5% according to LLPv2 was 
used as an inclusion criterium, together with an age of 50–75 years. Participants in 
this trial underwent LDCT-based screening or no screening. The percentage of 
participants with lung cancer identified in the LDCT arm at baseline (1.7%) was 
higher in UKLS than in the NLST or NELSON (1.03% and 0.9%, respectively)[28].  
Of note, NELSON involved current and former heavy-smokers (≥30 pack years) aged 
55–75 years who were randomly allocated to several rounds of chest LDCT-based 
screening or no screening. The LLPv2-based criteria used in the UKLS trial were 
subsequently adopted to select participants in the Liverpool Healthy Lung 
Programme[17]. The UK is currently leading the way in Europe in terms of 
implementing lung cancer early detection with LDCT-based screening, with major 
programmes ongoing in the Liverpool[17], Manchester[18], Yorkshire[20] and 
London[19,29] regions. Moreover, in 2019, NHS England provided major investment 
to introducing a national programme in ten new regions in 2019[30]. These new 
programmes will involve a combination of both the PLCOM2012 and LLPv2 risk models 
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to recruit participants, thus demonstrating interest in targeted recruitment 
approaches.  
In one of the most comprehensive analyses, nine different risk models were 
used to analyse data from the Prostate, Lung, Colon, and Ovarian cancer screening 
(PLCO) trial and NLST datasets[22]. The selected sophisticated models incorporated 
well-documented risk variables (such as family history of lung cancer, previous 
malignancy, previous respiratory disease and exposure to asbestos). However, not 
all risk factors were considered in these comparisons, which were only based on age, 
sex and tobacco-related factors, thus underestimating the lung-cancer risk of never-
smokers. The PLCOM2012 model had the best predictive performance in this analysis, 
with an area under the curve (AUC) >0.77. Several studies have also shown the cost-
effectiveness of screening in high-risk populations, leading to the conclusion that 
improved risk-prediction models would further reduce costs per life years (LYs) saved 
[22,31]. The cost-effectiveness analysis only revealed a modest gain of additional 
LYs. In addition, use of lung cancer prediction models increased the risk of 
overdiagnosis owing to preferential selection of older individuals; thus the 
researchers concluded that the future development of risk-based lung cancer 
screening needs to incorporate life expectancy[31].  
Using risk models in national screening programmes has potential limitations 
that must be acknowledged. In particular, information on risk variables has to be 
either available in primary health-care records or obtained directly from the patient. 
Collection of these data in the UK implementation studies has involved a two-step 
process, whereby all patients with a smoking history in the primary care notes and/or 
electronic health records were invited and then, a structured questionnaire was 
provided to them at the time they were consented into the studies. However, smoking 
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history is not always recorded in primary care notes and thus might be challenging in 
other countries and not a feasible approach. The advent of social media and the use 
of clinical apps might provide solutions for obtaining information on risk variables 
directly from patients, but these approaches remain in early stages of 
development.[32]  
 
Currently, none of the validated prediction models to identify individuals with a 
high risk of lung cancer have incorporated biomarkers or susceptibility genes, even 
though major efforts have been undertaken in this regard[33]. Integral, a major lung 
cancer programme from the NIH[34], is currently focused on this topic and has 
generated some early encouraging data on the integration of genetic susceptibility 
pathways[35–37] and circulating biomarkers[38] in risk-prediction models. Indeed, 
the next stage in the development of risk-prediction models will have to move beyond 
epidemiological and clinical data to also include validated biomarkers. This active 
area of research will require access to current CT-screening biobanks as well as the 
development of high-quality prospective biobanks embedded in future screening 
programmes together with radiomics data (volume and density growth 
characteristics). Future molecular tests not only need to be validated, but also cost-
effective, possibly using nanotechnology-based approaches [39].  
 
[H1] Recruitment and adherence issues  
The real-world experience in the USA, where only a fraction (<5%) of individuals at 
high risk of lung cancer are screened, demonstrates the difficulties in effective 
recruitment of participants in national screening programmes, even when they are 
endorsed by most major medical societies[40]. The challenges of recruitment and 
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screening adherence differ between regions because they depend on the nature of 
the health-care system as well as on the public and physician opinions on screening 
— clearly, a unique approach has to be chosen for each country. Nevertheless, two 
principles should be common to all approaches to recruitment: screening should only 
be implemented for high-risk individuals; and appropriate presentation of potential 
benefits and risks is crucial[41]. Experience from the UKLS trial has revealed that, 
especially in the first stage of recruitment, current smokers and individuals from lower 
socioeconomic groups are least inclined to participate[42,43]. For current smokers, 
emotional barriers seem to represent a central obstacle to screening 
participation[42]. More than ever, primary care physicians could be the focal point in 
ensuring screening uptake by individuals who are mostly likely benefit[40]. Other 
major contributors to the low uptake of screening might be the false-positive rate 
(when a nonmalignant nodule is detected; 24% [16])  
that was reported in the NLST trial[4] and also the perceptions of some patients and 
carers[44]. In the NELSON trial, however, with results published 9 years after those 
from the NLST and incorporating optimized nodule-management protocols and risk-
stratification algorithms, the false-positive rate was only 1.2% and the referral rate 
only 2.1%[10]. Of note, the definition of positive screen result differed between the 
NLST and NELSON study: in the NLST the two possible outcomes of a chest LDCT 
or radiography were ‘negative’ and ‘positive’, but in NELSON ‘indeterminate’ was 
introduced as a new classification[45,46]. Only when indeterminate nodules were 
found to have grown at a short-term follow-up LDCT scan was the indeterminate 
screen result reclassified as positive.  
Eventually, the successful recruitment of individuals at high risk of lung cancer 
will depend on the combined efforts of primary-care physicians and specialists. In 
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order to ease the pressure on the former, the responsibility for determining an 
individual’s eligibility has to be considered as a multidisciplinary activity and thus, 
discussions around shared decision-making, counselling for smoking cessation and 
potential treatment options should be combined across clinical specialties.  
Challenges in the recruitment of high risk and hard to reach individuals remain 
one of the major barriers to the implementation of lung cancer screening 
programmes. Even among the most efficient centres in terms of recruitment in 
ongoing UK implementation projects, few have a participation rate >50%[17–19].  
 
 
[H1] Radiological evidence 
 
 
The aim of lung cancer screening is to enable early detection of malignant nodules in 
order to eventually reduce cancer-related mortality. Before the 2010s, the technical 
performance of chest radiography, alone or in combination with sputum cytology, was 
evaluated in population-based lung cancer screening programmes[41,47]. However, 
these studies did not show reductions in lung cancer mortality and the screening 
method was proven not to be sensitive enough[47–49]. In the 2000s, the introduction 
of LDCT renewed interest in assessing the performance of imaging-based lung cancer 
screening approaches[47]. A chest LDCT entails a radiation dose of ~1.5 mSv, which 
is 15-fold higher than the dose delivered to obtain a conventional chest X-ray but <25% 
of that delivered with conventional chest CT[50].  
While other diagnostic methods, such as MRI or genetic testing, have been 
explored in population lung cancer screening, results from RCTs that would support 
their use in current clinical practice are not available[47,51,52]. Currently, LDCT-based 
lung cancer screening is the only screening approach that has resulted in a statistically 
significant reduction of lung cancer-related mortality in two independent sufficiently 
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powered RCTs (FIG. 2)[4,10]. In 2011, researchers from the NLST reported a 20.0% 
reduction in lung cancer-related mortality after a median follow-up of 6.5 years 
(P = 0.004) in patients undergoing three annual LDCT-based screenings compared 
with those undergoing chest radiography screening with the same frequency[4]. The 
overall mortality reduction in the LDCT group was 6.7% (P = 0.02). In 2020, results 
from the NELSON trial showed a cumulative rate ratio (RR) for death from lung cancer 
in men of 0.76 (95% CI 0.61–0.94) in the screening arm relative to the control arm at 
10 years[10]. The cumulative RR for all cause mortality was 1.01 (95% CI 0.92–1.11). 
Nevertheless, implementation of LDCT in screening programmes is still ongoing in the 
USA and anticipated in Europe in the next decade[41,47,53,54].  
 
 
[H2] Nodule prevalence and risk stratification  
Effective risk-stratification and management of detected lung nodules is crucial for the 
success of any lung cancer screening programme. Baseline nodules with an unknown 
developmental timeframe need to be distinguished from new nodules (after baseline) 
that have developed within a known timeframe[55]. Depending on the detection limit, 
22–51% of participants in screening RCTs have a lung nodule detected at baseline[56–
65]. Furthermore, available data from the Early Lung Cancer Action Project 
(ELCAP)[66], International (I)-ELCAP[63], Pittsburgh Lung Screening Study[56], Mayo 
trial[67], NLST[68] and NELSON trial[55] suggest that, annually 3–13% of participants 
develop a new nodule after any baseline screening, negative or positive. Importantly, 
the majority of lung nodules detected, either at baseline or thereafter, are small. Data 
from lung cancer screening trials with none or a very low detection limit (>3 mm or >15 
mm3; Mayo trial[67], ELCAP[66], I-ELCAP[63], NELSON[55]) suggest that >50% of the 
detectable lung nodules have a volume <50 mm3 or a maximum diameter 
<5 mm[55,57,58,60,61,66,67,69]. Similarly, the NLST (with a detection limit of 4 mm 
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for the longest diameter) revealed a baseline nodule prevalence of 51% for nodules of 
4–6 mm. The detection of multiple nodules is common in screening practice: ~50% of 
participants have more than one nodule at baseline and >20% of those who develop 




[H2] Nodule size assessment 
An accurate and reproducible assessment of nodule size is central to ensuring 
appropriate nodule management. The assessment of nodule size has been routinely 
based on the manual measurement of the longest diameter[72,73]. Nevertheless, this 
approach was shown to be unreliable when compared with subsequent methods, such 
as volumetry, because pulmonary nodules are seldom perfectly geometrically 
shaped[74,75]. Several European lung cancer screening trials (FIG. 2) have 
incorporated volumetry involving semi-automated volume estimation after 3D 
reconstruction of thin CT slices of nodules[6,10,51,55,61]. This approach was 
advocated in the European Statement on Lung cancer Screening (EUPS)[16] and was 
subsequently implemented in clinical practice guidelines from the British Thoracic 
Society (BTS), suggesting that whenever available, volumetry should be preferred to 
diameter measurements[47,72,76,77]. Moreover, in the 2019 Lung Imaging Reporting 
and Data System (Lung-RADS) screening guidelines, volume standards have been 
added as a more reproducible alternative to manual linear measurements whenever 





[H2] Nodule growth 
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With the use of appropriate size cut-offs, most nodules detected during lung cancer 
screening can be classified as low-risk or intermediate-risk nodules and decisions can 
be made on additional follow-up screens (regular (1 year) or short-term (3 months) 
according to the EUPS[16]). At follow-up screens, risk stratification should be based 
on nodule growth[47,72,76,77]. Again, considering that most nodules detected in lung 
cancer screening are very small, tumour growth assessment based on 2D diameter 
evaluation has been considered unreliable compared with volumetry[77]. For example, 
in the Lung-RADS screening guidelines, growth has been defined as an increase of 
>1.5 mm in diameter or >2 mm3 in volume[53]. In a spherical nodule with a diameter of 
5 mm (and thus, a volume of ~65 mm3), a diameter increase to 6.5 mm would result in 
a more than doubled volume (144 mm3) whereas a volume increase to 67 mm3 
corresponds to a diameter increase to only 5.04 mm. An analysis of 2,240 
intermediate-size nodules (defined as 50–500 mm3 in volume or ~4.5–10 mm in 
longest diameter), revealed a median intranodular diameter variation of 2.8 mm, above 
the 1.5 mm growth threshold, when volume was estimated on the basis of the 
maximum versus the minimum diameter[75]. Even when nodule diameter was 
measured semi-automatically, the intranodular variation was ≥2 mm in 85% of 
nodules[75,77,78]. Importantly, volume measurements have a significantly worse 
performance in areas with ground glass opacity and in the measurement of part-solid 
nodules[79]. In Asian populations, in which such nodules are more common[80], 
volume measurements alone might therefore not be the best option in nodule 
management, but a combination of the measurement of volume, mass and diameter 
of these subsolid nodules. Another advantage of volumetry is that it enables calculation 
of the volume-doubling time (VDT), a widely used surrogate for growth speed[47], as 
opposed to considering a fixed size increase, which translates into different growth 
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speeds at different nodule sizes. Even compared with software-guided and optimized 
diameter measurements, a protocol based on semi-automated nodule volume and 
VDT measurements yielded the highest specificity (94.9% versus 90.0% with the 
diameter-based protocol) and positive predictive value (14.4% versus 7.9% with the 
diameter-based protocol) with similar negative predictive value (99.9% in both 
protocols) in an analysis of data from the NELSON trial[77,81].  
 
 
[H2] Nodule subtypes 
Radiological detection enables the classification of pulmonary nodules into non-
calcified pulmonary nodules, which comprise solid and subsolid nodules, the latter 
including ground-glass (non-solid) nodules and part-solid nodules, and calcified 
nodules. From the perspective of lung cancer screening, this distinction is relevant for 
two reasons. Firstly, both at baseline screening and in subsequent rounds of 
screening, (new) subsolid nodules are considerably less prevalent than (new) solid 
nodules, and overall <10% of lung cancer screening participants present with non-solid 
nodules[47,82–84]. Secondly, compared with solid nodules, non-solid nodules 
(including premalignancies) are associated with an equivalent or a higher prevalence 
of lung cancer, but their indolent nature (they are nearly always stage I cancers or in 
the pre-stages of lung cancer) has been shown both in prospective studies and 
RCTs[82,83,85–89]. Data from the NELSON trial and EUPS have formed the basis to 




[H2] Overdiagnosis and false positives 
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The identification of clinically significant lung cancer while preventing overdiagnosis 
and false-positive results is a central challenge in LDCT-based lung cancer screening. 
In this regard, clinical decision-making upon detection of subsolid nodules is 
particularly challenging because they are more often malignant than solid nodules but 
have a slower growth rate[80]. Therefore, continuous benchmarking of risk-
stratification algorithms is essential. For example, a comparison of the screening 
results from NELSON (using a volume-based protocol) and the NLST (using a 
diameter-based protocol) showed substantial differences in false-positive baseline 
screening results, with positive-test rates of 2.1% versus 24%, positive predictive 
values of 43.5% versus 3.8% and false-positive rates of 1.4% versus 23.3%.  
 
 
[H1] Nodule-based risk-prediction models 
The potential of integrating nodule data from LDCT scans with the patient’s clinical 
and epidemiological information has enabled the development of nodule-based lung-
cancer risk models. In certain instances, these models have been used in clinical 
practice not only to manage the radiological diagnostic follow-up but also to calculate 
the most appropriate time for a follow-up scan. 
 In 2013, researchers from the Pan-Canadian Early Detection of Lung Cancer 
Study (PanCan) published several nodule-based risk-prediction models[90], now 
referred to as the Brock parsimonious model (PanCan-1) and the comprehensive 
model (PanCan-2).These models were developed using data from 1,871 participants 
in PanCan and validated using a dataset comprising 1,090 individuals involved in 
chemoprevention trials from the British Columbia Cancer Agency. These two high-
risk screening cohorts had been followed up for a minimum of 2 years to determine 
the probability of pulmonary nodules detected in LDCT screens being cancerous. A 
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cancer diagnosis was associated with female sex (P ≤0.02), larger size of the nodule 
(P <0.001), location of the nodule in the upper lung (P ≤0.02) and nodule spiculation 
(P ≤0.02). These researchers also developed so-called ‘full models’, which 
additionally included older age, a family history of lung cancer, emphysema, lower 
nodule count and part-solid nodules as compared with solid nodules. These models 
had very good predictive accuracy, with AUCs >0.94 in the external validation cohort, 
and thus became the management tool recommended by EUPS and BTS[16,76]. In 
2019, PanCan included nodule volume in these models[91]. Both the diameter-based 
and volume-based models showed very good overall predictive performance in the 
test and validation datasets, with accuracy similar to that of the previously validated 
PanCan models: the computer-aided detection (CAD)-assessed mean diameter and 
volume models both had median AUCs of 0.947 in the PanCan data and of 0.810 
and 0.821, respectively, for the NLST dataset[91]. 
The UKLS dataset has also been used to develop a parsimonious model to 
estimate the probability of malignancy in lung nodules detected at baseline, 3-month 
and 12-month repeat screens[92]. The covariates found to enable prediction of lung 
cancer included female sex, asthma, bronchitis, asbestos exposure, a history of 
cancer, a family history of early and late onset of lung cancer, smoking duration, lung 
forced vital capacity, nodule type (pure ground-glass and part-solid) and larger volume 
(measured by semi-automated volumetry). The final model incorporating all predictors 
had excellent discriminatory value (with an AUC of 0.885). Internal validation 
suggested that the model would discriminate well when applied to new data in the 
future (with an AUC of 0.882) and had good calibration when used with ‘bootstrapping’ 
optimization techniques.  
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A number of groups have attempted to develop other nodule-based risk-
prediction models. The Pittsburgh Lung Screening Study cohort constitutes one such 
approach using probabilistic graphical models to integrate demographics, clinical data 
and LDCT scan-related features[93]. The investigators noted that the number of 
nodules and blood vessels as well as the number of years since the individual quit 
smoking were sufficient to discriminate malignant from benign nodules, with 
statistically significant coefficients (P <0.05). The incorporation of LDCT scan-related 
features greatly enhanced the predictive accuracy of this model, improving cancer 
detection over existing methods, in particular, the Brock parsimonious model 
(P <0.001). The most notable observation of this study is that the incorporation of 
information on the number of surrounding vessels significantly improves on the 
predictive efficiency of previous models[93].  
 
In the German Lung cancer Screening Intervention (LUSI) trial[6], 4,052 long-term 
smokers aged 50–69 years were randomly allocated to undergo five annual rounds 
of LDCT-based screening or no screening. Data from this trial were used with the aim 
of validating several nodule-based risk models, such as the PanCan[91], Mayo 
Clinic[94], Peking[95] and UKLS models[92] using sophisticated statistical tools[96]. 
PanCan-1b was found to be the model with the most predictive value in this 
validation exercise (AUC 0.93) and the UKLS model was considered the least 
optimal, (UKLS: AUC, 0.58) although the study design did not take into account that 
some of the UKLS model parameters were not available in the original LUSI dataset, 
such as family history and exposure to asbestos. By leaving these two variables out 
and using the other coefficients in the model unchanged, will most likely give biased 
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estimates. The editorial associated with this publication outlined the pro’s and con’s 
of attempting validation of these risk models[96,97]. 
 
This study exemplifies the importance of including parameters with a low risk 
of inter-reader variability in risk models. The inclusion of parameters with a high risk 
of inter-reader variability, such as diagnosis of bronchitis or discrimination between 
part-solid and non-solid lung nodules, might strongly reduce the performance of 
these models for predicting outcomes in cohorts others than those with which they 
were developed[97]. Of note, all the models discussed herein have reduced 
performance when used on nodules newly detected after baseline, confirming the 
need for separate management protocols for these nodules. 
 
 
[H1] Screening frequency  
In LDCT-based lung cancer screening, the duration of the interval between two 
regular screening rounds (referred to as screening interval) is a crucial determinant of 
the benefit:harm ratio. By prolonging this interval, cumulative radiation and diagnostic 
costs decrease, but the probability of a cancer diagnosis outside of the screening 
programme (so-called ‘interval cancers’) and/or that of detecting late-stage lung 
cancer increase. In the USA, lung cancer screening is currently performed through 
annual LDCTs in high-risk patients, on the basis of the USPSTF recommendations, 
which in turn are based on the NLST criteria[98]. All countries recommend an annual 
screening interval; however, the outcomes of the NELSON study suggests that a 
sex-specific interval could be applied in the future, because nodules tend to have a 
slower growth rate in women than in men[10].  
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With the increasing interest in patient-tailored medicine, the question has 
arisen of whether decisions regarding future screening rounds should be made on 
the basis of the baseline screening result, enabling the identification of subgroups of 
patients with lower lung cancer risk who might benefit from a biennial screening 
interval. To date, evidence from three screening trials (the NLST, Multicentric Italian 
Lung Detection (MILD) trial and NELSON) contribute to this debate.  
 
Patz et al.[99] retrospectively evaluated the value of annual follow-up LDCT 
after a negative baseline screening result among participants in the NLST. Among 
19,066 NLST participants with a negative baseline result, 441 (2%) were eventually 
diagnosed with lung cancer. Lung cancer was diagnosed within 2 years after the 
baseline scan in 92 individuals (0.48%, with 30 interval cancers and 62 screen-
detected cancers), 52% with stage I–II cancers. An additional 118 participants had 
lung cancer diagnosed ≤1 year after the third screening (and thus, 2–3 years after 
the baseline scan), with 60% having stage I–II cancers. Owing to the very low 
incidence of lung cancer in the first annual screening round after baseline in 
participants with a negative baseline LDCT scan, Patz et al.[99] concluded that 
annual screening might be superfluous in these situations.  
 
In the MILD trial, participants with a high risk of lung cancer (49–75 years of 
age, who smoked ≥20 pack-years, and were current smokers or quit <10 years 
before recruitment) were randomly assigned to undergo annual screening 
(n = 1,190), biennial screening (n = 1,186), both for a median follow-up of 6 years, or 
no screening (control group n = 1,723). Ten years after the baseline scan, LDCT-
based screening (annual and biennial combined) was associated with a significant 
39% reduction in lung cancer-related mortality (HR 0.61, 95% CI 0.39–0.95; 
P = 0.017), as well as a nonsignificant 20% decrease in all-cause mortality (HR 0.80, 
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95% CI 0.62–1.03; P = 0.069)[7]. In an additional analysis of the results of MILD, 
Pastorino et al.[100] showed that lung cancer-related mortality (HR 1.10, 95% CI 
0.59–2.05) and overall mortality (HR 0.80, 95% CI 0.57–1.12) at 10 years after 
baseline screening were similar for participants in the biennial and annual LDCT 
arms. In this trial, the biennial screening protocol enabled avoidance of up to 44% of 
follow-up LDCT scans, without an increase in the occurrence of stage II–IV or interval 
lung cancers. Although the sample size of the MILD trial was underpowered, these 
results suggest that individuals with a negative baseline result might benefit from 
undergoing biennial instead of annual screening.  
 
Another approach to addressing whether the screening interval should be 
considered on an individual basis has been proposed on the basis of a logistic 
regression model of lung cancer risk at the second annual screen or in the following 
year. This model, which was only tested retrospectively, included participants’ 
characteristics and radiological observations, such as nodule characteristics at the 
first screen, using NLST data[101]. For different risk thresholds, Schreuder et al.[101] 
projected that 2,558 (10.4%), 7,544 (30.7%), 10,947 (44.6%), 16,710 (68.1%) and 
20,023 (81.6%) of 24,368 second screens could have been omitted, at the cost of 
delaying the diagnosis of 0 (0.0%), 8 (4.6%), 17 (9.8%), 44 (25.3%) and 70 (40.2%) 
of 174 lung cancers, respectively, thus concluding that the screening interval could 
be extended for certain participants. 
 
In NELSON, the effect of prolonged screening intervals was studied by 
incorporating different intervals between each repeat round of screening. Participants 
randomly allocated to the LDCT arm were screened at baseline (year 1) and then in 
years 2, 4 and 6.5; resulting in one annual screening round, one biennial screening 
round and one 2.5-year screening round, respectively. The probability of lung cancer 
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2 years after the baseline scan was determined. Participants with a negative baseline 
CT, with a newly proposed cut-off volume for the largest nodule <100 mm3, had a 
similar very low risk of being diagnosed with lung cancer within 2 years as 
participants without any baseline nodule (0.6% versus 0.4%, respectively). For 
participants without any baseline nodule, the 2-year probability of lung cancer was 
significantly lower than that of participants with intermediate risk nodules (100–300 
mm3; 2.4% probability) or high-risk nodules (>300 mm3; 16.9%) at baseline, again 
suggesting that an annual LDCT after a negative baseline CT might not be necessary 
for some patients. In the NELSON study, the number of interval cancers and stage 
II–IV lung cancer detected after a screening interval of 2.5 years was higher (the 
former significantly[ FIG 2] [Au: P value?] ) than those detected at annual and 
biennial screening rounds, indicating that a screening interval >24 months might be 
too long[102]. 
 
 These studies show the added value of patient stratification on the basis of the 
results from the baseline LDCT scan; however, this stratification approach leads to 
questioning of the value of risk assessment before testing. For example, if an 
individual is already eligible for screening, is further stratification on the basis of the 
baseline screen a correct approach? If the baseline result was negative, should this 
patient not have been invited for screening at all? Nevertheless, using the baseline 
screening result as an additional, independent, lung-cancer risk stratification together 
with variables specific for each participant to determine eligibility might help to reduce 
the number of unnecessary screenings[103] (TABLE 1).  
 
[H1] Sex differences in lung cancer 
Lung cancer screening trials have revealed differences in lung cancer-specific 
mortality between men and women. Shortly after the publication of the NLST 
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mortality results at a median follow-up duration of 7.5 years, a detailed analysis of 
these results stratified by several factors was presented[104]. In this analysis, lung 
cancer incidence and mortality was evaluated up to 31 December 2009, instead of 15 
January 2009, the date in the original publication[4]. Lung cancer screening was 
found to be beneficial to a higher extent in women than in men (TABLE 2), although 
this interaction was not statistically significant (P = 0.08). Updated results from the 
NLST were published after an extended follow-up duration of 11.3 years for lung 
cancer incidence and 12.3 years for mortality[105], a period in which potential 
confounding owing to participation in the screening programme would be diluted. The 
investigators found a beneficial effect for women, with lung-cancer mortality RRs in 
dilution-adjusted analysis of 0.89 (95% CI 0.80–1.00), 0.95 (95% CI 0.83–1.10) and 
0.80 (95% CI 0.66–0.96) in the overall study population, men and women, 
respectively, although when directly compared, the difference between men and 
women was not statistically significant. The number of patients with stage IV disease 
was 468 in the LDCT arm versus 597 in the radiography arm; this difference was 
larger for women (165 and 232 patients with stage IV disease in the LDCT and 
radiography arms, respectively) than for men.  
 
The NELSON outcomes published after 10 years of follow up were focused on 
the effect of screening in male participants, owing to the low number of women 
involved in the trial (TABLE 2). Nevertheless, lung cancer-specific mortality outcomes 
were more favourable for women than men, although the 10-year lung cancer-
specific mortality results were not statistically significant in women (RR 0.67, 95% CI 
0.38–1.14). At 7, 8 and 9 years after baseline LDCT-based screening, the magnitude 
of lung cancer-specific mortality reduction was greater in women than in men, with 
RRs of 0.46 (95% CI 0.21–0.96) versus 0.79 (95% CI 0.60–1.03) at 7 years, 0.41 
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(95% CI 0.19–0.84) versus 0.76 (95% CI 0.60–0.97) at 8 years and 0.52 (95% CI 
0.28–0.94) versus 0.76 (95% CI 0.61–0.96) at 9 years. At 11 years, and thus 5.5 
years after the last screening round, the RR was 0.78 overall, indicating the 
importance of repeated screening and the length of screening intervals.  
 
In the LUSI trial, the difference in lung cancer mortality between individuals in 
the LDCT screening and no screening arms was not statistically significant (HR 0.74, 
95% CI 0.46–1.19; P = 0.21), possibly owing to the small size of the intervention 
population (TABLE 2)[6]. However, lung-cancer specific mortality was significantly 
lower in the screening arm when considering women alone (HR 0.31, 95% CI 0.10–
0.96; P = 0.04).  
 
Taken together, the sex-specific subgroup analyses of the NLST, NELSON 
and LUSI trials suggest that lung cancer screening could have a more beneficial 
effect in women than in men, with trends towards fewer late-stage cancers and fewer 
lung cancer-related deaths in women undergoing LDCT-based screening. The 
outcomes of these trials are consistent with estimates of the sensitivity of lung cancer 
detection and mean preclinical durations established through modelling of the natural 
history of lung cancer using data from the PLCO trial[106] and other clinical studies. 
In a Swedish cohort study including >23,000 patients with lung adenocarcinomas 
(LUADs) or squamous cell carcinomas of the lung, women presented with a better 
performance status, were younger and more often never-smokers at the time of lung 
cancer diagnosis compared with men (P ≤0.04). Furthermore, women diagnosed with 
LUAD had a lower comorbidity burden, had tumours of a less advanced stage and a 
higher proportion of EGFR-mutated tumours than men (P <0.001). When comparing 
survival outcomes on the basis of tumour stage at the time of detection, lung cancer-
specific survival was consistently less favourable for men than for women, with a HR 
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of 0.69 (95% CI 0.63–0.76) for stage IA–IIB LUADs and 0.94 (95% CI 0.88–0.99) for 
stage IIIB–IV LUADs[107]. Similar results from other large-cohort studies, including a 
study using data from the Surveillance, Epidemiology, and End Results (SEER) 
database, have shown a beneficial effect of LDCT-based screening on lung cancer-
specific survival in women. An analysis of outcomes involving 24,671 men (51.7%) 
and 23,035 women (48.3%) from this cohort revealed that 5-year lung cancer-specific 
survival was significantly worse for men than women (HR 1.24, 95% CI 1.20–1.28; P 
<0.001), even after adjusting for age, ethnicity, performance status and smoking 
status[108]. Future studies could help to establish whether the use of different lung-
cancer screening guidelines for men and women could improve screening 
performance.  
 
[H1] Integrated smoking cessation 
 
Many experts in public health have proposed to integrate smoking-cessation 
interventions within LDCT-based screening programmes in the future. For example, 
the EUPS recommends offering advice on smoking cessation to all current 
smokers[47]. The NLST and UKLS provide evidence on the effect of in-trial events on 
smoking cessation. In the NLST analysis, individuals were significantly more likely to 
quit smoking if abnormal results had been observed in the previous year's screen (P 
<0.0001)[109]. Differences in smoking prevalence among participants in the NLST 
trial were detected up to 5 years after the last screen. Around the same time as the 
publication of this analysis of the NLST data, results from the Danish Lung Cancer 
Screening Trial were published. In this trial, 4,104 participants with a smoking history 
were randomly assigned to undergo annual LDCT-based screening or no screening. 
At 5 years, no significant differences in annual smoking status were detected 
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between the LDCT group and control group[110]. In fact, the results of this trial were 
disappointing because the percentage of ex-smokers in both groups combined 
significantly increased from 24% at baseline to 37% at year 5 of screening 
(P <0.001)[110]. The findings from the UKLS trial support those from the NLST 
trial[111] and are opposed to those from the Danish Lung Cancer Screening Trial. In 
the UKLS, independent of the screening result, smoking-cessation rates were 8% (36 
of 479 individuals) and 14% (75 of 527) in the control and intervention arms, 
respectively, 2 weeks after baseline scan results or control assignment, and 21% (79 
of 377) versus 24% (115 of 488) up to 2 years after recruitment. Participants with a 
positive screening result were more likely to quit in the longer term compared with 
those in the control group (P = 0.007) and those receiving a negative result (P 
<0.001)[111]. This observation raises the question as to whether smoking-cessation 
programmes are only effective in participants requiring an intervention for cancer and 
suggest that such programmes might not have been successfully integrated yet into 
LDCT-based lung cancer screening — addressing this challenge clearly requires 
further innovative research. The Yorkshire Lung cancer screening trial (UK) has a 
ground-breaking ongoing study to integrating smoking cessation and CT screening 
[20]  
Kummer et al.[112] have identified different patterns of response to patient 
participation in screening programmes, both from a psychological and behavioural 
point of view. Their analysis indicated that the simplistic concept linking smoking 
cessation with involvement in a CT-based screening programme needs to be 
reconsidered. These programmes require a more in-depth research agenda to 
ensure that communication of the screening pathway is designed to promote well-
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being, motivate positive behavioural change and, in particular, smoking cessation, 
ultimately maximizing patient benefit. The fact that lung cancer screening of high-risk 
participants presents a learning opportunity for smoking cessation should be 
acknowledged, especially among individuals who receive a positive scan result. 
Nevertheless, further behavioural research is urgently required to evaluate optimal 
strategies for integrating smoking-cessation interventions within stratified lung cancer 
screening, which would lead to further reduction in smoking-related morbidity and 
mortality. 
 
[H1] Cost effectiveness of lung cancer screening  
Any innovative health-care technology — with either curative or preventative intent — 
requires appraisal from health regulators of its added value. Owing to budget 
constraints, decision-makers must consider the economic aspects associated with a 
new technology, analysing the balance between additional costs and health-care 
benefits through cost-effectiveness analyses. In some countries, innovations such as 
lung cancer screening might not be introduced if they are not considered cost-
effective. Therefore, these analyses can be crucial in discussions of national lung 
cancer screening programmes. In this context, a cost-effectiveness model would 
compare a theoretical population that is screened — with all its additional costs, 
savings and health benefits — with the same population in the absence of screening. 
Health benefits are expressed as LYs or quality-adjusted (QA) LYs gained. Although 
screening does not directly create health benefits per se, it enables early detection of 
lung cancer and thus improved treatment options, which can result in health benefits. 
In these models, input parameters on costs and health benefits are often required to 
be country specific, while screening-related parameters (such as efficacy, sensitivity 
and specificity) are based on data from large screening trials. Results are expressed 
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as the incremental cost-effectiveness ratio (ICER), reflecting net costs per QALY or 
LY gained. 
 
Several cost-effectiveness studies on lung cancer screening have been 
performed using datasets from various specific clinical studies as an input, while 
accounting for different scenarios[113–124] (FIG. 4). Using country-specific 
thresholds for cost-effectiveness, most studies have demonstrated that lung cancer 
screening can be cost-effective, with ICERs of US$15,000–100,000 per QALY 
gained and $20,000–62,000 per LY gained. For example, ten Haaf et al.[119] 
considered a scenario in which participants were assumed eligible for screening if 
they were aged 55–75 years, had smoked >40 pack years and were current smokers 
or had quit <10 years before the first screen. On the basis of several simulations, 
lung cancer screening was considered cost-effective against the threshold of 
CAD$50,000 per QALY. In the UK, a cost-effectiveness model was developed, which 
was utilised in the UKLS trial[125]. In addition, the UKLS trial investigators reported 
an estimate cost of ~£8,500 per QALY gained in individuals undergoing screening, 
although this value was subject to a number of uncertainties[28], as it was only based 
on the UKLS pilot data.  
 Both annual and biennial screening programmes have been deemed as 
potentially cost effective. Goffin et al.[118] specifically compared both strategies in a 
scenario using the NLST eligibility criteria. They concluded that biennial screening 
used fewer resources and, although associated with lower gains of LYs, resulted in 
very similar gains of QALYs over a timeframe of 20 years. These researchers 
estimated that the ICER of annual compared with biennial screening was 
US$54,000–4.8 million/QALY gained, which would make biennial screening more 
cost-effective. However, ten Haaf et al.[119] concluded that annual screening was 
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more cost-effective than biennial screening, although less-intensive screening with 
longer intervals could also represent a cost-effective approach.  
 
The situation in the USA, where $100,000 per QALY is considered cost-
effective by the federal health-care system (Centers for Medicare & Medicaid 
Services (CMS)), is very different from that in Europe (50,000 euro or $55,000) and 
the UK (£20,000–30,000; FIG. 4). Criss et al.[115] developed four models that 
showed that the NLST, CMS and USPSTF screening strategies were all cost-
effective in the USA, with ICERs averaging $49,200, $68,600 and $96,700 per 
QALY, respectively. The main difference between these strategies is the maximum 
age at which to stop screening (80 years, 77 years and 74 years, respectively). This 
analysis highlighted exactly where the costs lay and the five greatest areas 
contributing to the total costs associated with screening programmes, noting that the 
major one is the actual LDCT screening itself. Nevertheless, the major limitation of 
this analysis was that risk prediction models for the selection of participants, which 
could potentially increase the cost-effectiveness of screening, were not factored in. 
The authors indicated their plan to address this aspect in future projects from the 
Cancer Intervention and Surveillance Modeling Network. While using a risk prediction 
model can increase the cost-effectiveness of a screening programme, related issues 
that have not been investigated in this context include the tendency of the target 
population to have comorbidities and therefore a shorter life expectancy and 
potentially a lower quality of life. The latest publication of results from the NELSON 
trial warrants new cost-effectiveness analyses to assess the financial implications of 
volumetric-based lung screening[10]. The increased availability of data from patients 
with lung cancer and, in particular, from screening programmes, will make future 
cost-effectiveness analyses more robust and therefore better suited to assist 
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decision-makers on designing and introducing LDCT-based lung-cancer screening in 
national programmes. Future cost-effectiveness models could encompass multiple 
perspectives, such as the health-care and societal perspectives, as well as a fiscal 
perspective to better determine the financial implications of introducing national lung-
cancer screening programmes. Future cost-effectiveness models should also take 




[H1] Current opportunities worldwide 
 
[H2] Screening in China  
Lung cancer has been the leading cause of cancer-related death in China since 
2005, with an age-standardized 5-year survival of only 19.7% in 2015[126]. Data 
from the National Central Cancer Registry of China (NCCRC) in 2014revealed that, 
on average, >10,400 lung cancers were diagnosed daily and >6,200 lung cancer-
related deaths occurred each day[127]. Lung cancer mortality in China has been 
projected to increase by ~40% between 2015–2030[128]. Compared with countries in 
Europe and North America, in most Asian countries lung cancer is more frequent 
even in non-smokers[129], suggesting that Asian countries might need to use lung-
cancer screening guidelines different from those we have discussed in previous 
sections. 
 
One of the earliest lung cancer screening programmes in China was initiated 
in 2009 and involved a rural population in the Yunnan Province[130]. Since 2012, the 
Ministries of Finance and Health of China have included lung cancer screening in the 
national cancer early detection and treatment programme for the urban 
population[129]. A modelling study revealed that LDCT-based screening in urban 
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areas of China would lead to a 17.2% and 24.2% reduction of lung cancer-related 
mortality compared with chest radiography-based screening and no screening, 
respectively[131]. In Shanghai, a total of 14,506 individuals were involved in an 
LDCT-based lung cancer screening study[132]. The preset positive result of 
screening was defined as nodules of any size and any density. The lung cancer 
detection and incidental detection (that is, detection of any abnormality other than 
lung cancer) rates were 29.9% and 1.2%, respectively, with an incidental detection 
rate of stage I lung cancer of 0.97%. The frequency of detection of nodules with a 
diameter <5 mm was 74.9%, although 94.1% lung cancers detected were ≥5 mm, 
and the frequency of detection of non-solid nodules was 84.9%. Therefore, the 
baseline LDCT-based lung cancer screening round revealed that subsolid nodules 
accounted for the majority of lung cancers in the study population and that a diameter 
of 5 mm is the recommended threshold for positive results[132].  
 
LDCT-based lung cancer screening has gained popularity in China; however 
the definition of the high-risk population and the high number of false-positive results 
remain two challenges that need to be addressed. Previous studies have shown that 
the criteria used in Europe and North America to determine individuals at a high risk 
of lung cancer might not be suitable for the Chinese population, especially 
considering the high incidence of lung cancer in females and non-smokers in 
China[133]. Optimization of the eligibility criteria and identification of (new) risk 
factors associated with lung nodule detection are crucial aspects for improving the 
sensitivity and specificity of LDCT-based lung cancer screening in China. The 
definition of high-risk criteria in the screening population will depend on the results of 
future and ongoing multicentre RCTs. Considering the geographic and lifestyle 
variations across the country, specific high-risk criteria for the major regions might 
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need to be proposed to account for differences in external high-risk factors, such as 
exposure to air pollution in the afternoon, to radon (indoors), kitchen fumes and 
secondhand smoke. Family history and genetic susceptibility should also be 
considered. Identifying subpopulations at high risk of lung cancer, should be a clear 
priority in China, because no large epidemiological data sets have thus far been used 
to assess risk parameters for screening eligibility.  
The challenge posed by the high-number of false-positive results is mainly 
caused by cultural perceptions. In our experience (SY.L.), the medical environment of 
China tends to favour cautiousness from both clinicians and patients, which could 
result in overtreatment. A large number of small or intermediate sized (<5 mm) lung 
nodules that are detected in >75% of all participants turned out to be benign [132]; 
however, this result increases apprehension in the general population. Currently, the 
number of nodules with a diameter <3 mm detected is increasing, especially with the 
development of AI-based approaches; even for these small nodules, in practice 
invasive treatment is often preferred over watchful waiting.  
 
 An extensive review of lung cancer screening in China published in 2019[129] 
demonstrated a great deal of lung cancer screening activity throughout the country. 
Most of these programmes, however, have reported only preliminary results, mainly 
through websites and meeting abstracts, and thus, the available data need to be 
interpreted cautiously. The authors of this Review have reported that 23 lung-cancer 
screening programmes have been completed or are ongoing in China since the 
1980s, mainly after 2000[129]. Of note, the entry criteria are generally not smoking-
stringent owing to the existence of different lung cancer high-risk subpopulations in 
China. In this country, the evidence for LDCT-based screening implementation is 
mainly based on results of RCTs conducted elsewhere. Looking into the future, 
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LDCT-based screening programmes incorporating smoking cessation would result in 
greater benefits for participants. The recommendations advocated in this extensive 
Review of lung cancer screening in China are pertinent to future success and need to 
be implemented[129] (Supplementary Table 1). Further research in China, where 
lung cancer is now considered an epidemic, is urgently required. 
 
[H2] Screening in Japan and South Korea  
To date, few studies have reported on the efficacy of LDCT-based lung cancer 
screening in non-smokers and light-smokers[134]. In Japan, one such study was 
initiated in the Hitachi district which included a large proportion (~30%) of individuals 
aged 50–64 years with a smoking history of <30 pack-years[135,136]. Lung cancer 
mortality in this district following screening was found to differ significantly with that in 
the whole of Japan (2005–2009), with a standardized mortality ratio of 0.76 (95% CI 
0.67–0.86; P <0.001). In women, the reduction in standardized mortality ratio was 
also significant (0.74, 95% CI 0.56–0.97); of note, ≥90% of women were non-
smokers[135]. These results suggest that LDCT-based screening can lead to a 
decline in lung cancer-related mortality both in non-smokers and smokers, although 
Sagawa and colleagues identified a number of limitations in this study, such as trial 
design, with CT scans only in year 1 and year 6.  
The National Korean Lung Cancer Screening Project (K-LUCAS) is a single-
arm trial aimed at a high-risk population of individuals[137]. The pilot study included 
256 individuals and its purpose was to assess the feasibility of a multicentre 
nationwide programme using the K-LUCAS protocol[137]. The inclusion criteria for K-
LUCAS were 55–74 years of age, current or former smokers (who had quit smoking 
<15 years) and ≥30 pack-years smoking history. In a pilot test of this trial involving 
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256 participants, 10 nodules classified as grade 3 according to Lung-RADS were 
identified, 9 grade 4 nodules were identified and one participant was diagnosed with 
lung cancer. In addition, 86.3% of participants said they would participate in future 
lung cancer screening programmes and the average degree of willingness to quit 
smoking among current smokers was 12.7% higher than before screening.  
 
[H1] Future opportunities using AI  
  
The implementation of large lung cancer screening programmes has led to a massive 
increase in the workload of radiologists[138]. In parallel, technical improvements in 
LDCT have enabled small-sized pulmonary nodules to be visualized. Over the past 
decades, efforts have been made to improve screening procedures using AI-based 
strategies to detect and classify pulmonary nodules. Before these algorithms are 
implemented in routine clinical care, their performance should be proven to be robust 
in external datasets. 
 
[H2] Computer-aided detection systems 
Different CAD systems have been developed to assist radiologists in identifying 
relevant nodules. The use of CAD, however, remains challenging. A volumetric chest 
LDCT scan contains >9 million voxels. A lung nodule with a diameter of 5 mm 
occupies ~130 voxels, or only 1.4x10−5 of the lung volume[139]. False-negative 
results (when a clinically significant nodule is not detected) and especially false-
positive findings can be common; adding the result of CAD-based assessment to that 
of a radiologist led to a significantly better performance that from combining of two 
CAD systems without a human reader (97–99% versus 85–88%; P <0.03)[140].  
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The effect of CAD as a second reader has been studied in different LDCT-
based lung cancer screening trials. Within a subset of 400 patients from the NELSON 
trial that had been double-read by radiologists, 22% of nodules ≥50 mm3 were 
identified solely by CAD, including one lung cancer[141]. Liang et al. showed that 
four different CAD systems enabled the identification of 56–70% of 50 tumours (with 
a mean diameter of 4.8 mm) that had been missed on the prevalence round of the I-
ELCAP study, but failed to identify 20% of lung cancers identified by 
radiologists[142]. These results suggest that CAD has potential value as a second 
reader in LDCT-based lung cancer screening, although this approach is currently not 
currently part of routine clinical care. The detection rate of current standard LDCT 
was evaluated using maximum-intensity-projection (MIP; a type of CAD) or two 
different CAD systems. These systems were associated with comparable incremental 
sensitivity, with reporting times and false-positive rates favouring MIP[143,144]. 
Unlike the capabilities of radiologists, however, CAD systems keep being 
substantially improved over time owing to advances in neural network and AI 
systems[143,145], and thus these systems might have a role in lung cancer 
screening in the future. 
 
[H2] Lung nodule classification 
Deep learning (DL)-based approaches can help to accurately distinguish benign from 
malignant lung nodules, as reported in two large-cohort studies published in 
2019[146,147]. Ardila et al.  estimated lung cancer risk with a DL approach mainly 
based on changes in nodule volume[146]. The training set and test set included data 
from 42,290 and 6,716 NLST participants, respectively, and the algorithm was 
validated retrospectively in an independent clinical dataset including 1,139 
 34 
individuals[146]. Lung cancer risk estimation was restricted to 1-year after LDCT. For 
the 6,716 participants (including 86 with cancer) in the test set, the model achieved 
an AUC of 94.4% (95% CI 91.1–97.3%). A similar result was achieved in the external 
validation set (1,139 individuals, 27 with cancer), with an AUC of 95.5% (95% CI 
83.1–98.0%). Huang et al.[147] focused on nodule classification at the annual follow-
up scan rather than at the baseline LDCT scan. Using a DL algorithm (referred to as 
DeepLR), they identified nodule features predictive of malignancy. For the training 
set, they used baseline and follow-up LDCT data from 25,097 NLST participants who 
had undergone at least two LDCT scans. DeepLR was validated in 2,294 participants 
from the PanCan study; among this high-risk population, the algorithm enabled to 
identify a low-risk group (55%) with an estimated probability of developing lung 
cancer in the following 2 years of only 0.2%. DeepLR outperformed Lung-RADS in 
predicting lung cancer-related mortality risk (HR 16.07, 95% CI 10.15–25.44; P 
<0.0001). In addition, DeepLR was associated with a very high true-negative nodule 
rate, which could enable the potential identification of individuals who would benefit 
from repeat screening every 2–3 years as opposed to the current recommendation of 
annual screening[147].  
Baldwin et al.[148] compared the performance of an AI-based algorithm, the 
Lung Cancer Prediction Convolutional Neural Network (LCP-CNN), with that of the 
Brock parsimonious model in discriminating between benign and malignant 
pulmonary nodules. Three radiology datasets from the UK were used in this analysis, 
which revealed AUCs of 89.6% and 86.8% for the LCP-CNN and the Brock 
parsimonious model, respectively (P ≤0.005). The percentage of nodules with a 
score below the lowest category for cancer, and thus not requiring short-term follow-
up, were 24.5% and 10.9%, respectively. Of note, this study was performed on a 
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clinical trial dataset with a lung cancer prevalence of 19.3%, which is in contrast with 
the prevalence typical in lung cancer screening settings (1–3%) and thus, the 
performance of LCP-CNN in a screening setting is currently unknown.  
AI also has potential to enable the discrimination of different types of lung 
nodules. A total of 12,754 thin-section chest LDCT scans were retrospectively 
collected for training, validation and testing of DL-based convolutional neural network 
(CNN). Pulmonary nodules from these scans were categorized into four types: solid, 
subsolid, calcified and pleural. The DL model enabled the detection of most of the 
nodules when choosing a low-specificity standard. This model had a sensitivity and 
specificity of 99.57 (95% CI 98.62–100.00) and a specificity of 28.03 (95% CI 25.51–
30.62) compared with 97.44 (95% CI 95.26–99.18) and 29.23 (95% CI 26.69–31.88), 
respectively, using the Brock parsimonious model. The success of this model relied on 
the combination of two CNN structures[149]. 
 
[H1] Conclusions 
The results from several RCTs of LDCT-based lung cancer screening, including 
NELSON, have now provided conclusive evidence of a mortality reduction associated 
with the implementation of lung cancer screening in individuals from both sexes 
deemed at a high risk of lung cancer[10,150]. The lung cancer community now has 
the opportunity to focus on implementation research, guided by objectives that we 
have identified thanks to the advances of the past decade (BOX 1). The results of 
these research programmes will help to consolidate international opinion and guide 
national policy-makers in designing the most appropriate lung cancer screening 
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FIG. 1 | Screening Planning and Implementation RAtionale for Lung cancer. Herein we 
present a framework to define the scope of future implementation research on lung cancer 
screening programmes, referred to as  Screening Planning and Implementation RAtionale for 
Lung cancer (SPIRAL). 
 
FIG. 2 | Randomized controlled trials of LDCT-based approaches to lung cancer 
screening. Timeline of randomized-controlled trials (RCTs) of low-dose computer 
tomography (LDCT)-based lung-cancer screening, showing time from the recruitment date to 
the end of follow up and relevant findings associated with each trial. Of note, the mortality 
data are expressed with a P value excepting for all RCT excepting NELSON, for which 
confidence levels are provided. CXR, chest radiography; LDCT, low-dose computer 
tomography; PY, packet years; vs, versus; yr, years. aRCTs performing CT volumetry. 
 
FIG. 3 | Risk-stratification protocols for LDCT scan-detected lung nodules. a | Non-
calcified solid nodules detected at baseline low-dose computer tomography (LDCT) scans. b | 
New non-calcified solid nodules detected after baseline LDCT scans. c | Non-calcified 
subsolid nodules detected at baseline or new nodules detected after the baseline scan. These 
protocols are based on the data from the NELSON trial (Publication Ref). d, days; VDT, 
volume-doubling time; vs, versus. 
 
FIG. 4 |  Cost effectiveness of LDCT-based lung cancer screening.  Selected published 
cost-effectiveness analyses of low-dose computed tomography (LDCT)-based lung cancer 
screening[113–124], with results showing incremental cost-effectiveness ratios (ICER) per 
quality-adjusted life-years (QALY) or per life-years gained (LYG). The studies are sorted by 
country, and country-specific thresholds for willingness to pay (WTP) are provided. Data are 
presented in US$ (with conversion, if necessary) and adjusted to reflect pricing levels in 2019. 




FIG. 5 | Fifty-year timeline of lung cancer LDCT-based screening and implementation 
planning. Evidence-based lung cancer screening trials started in the 1970s with trials of chest 
radiography (CXR)and continued with the pioneering work in low-dose computed 
tomography (LDCT) undertaken in the International Early Lung Cancer Action Project (I-
ELCAP), the US National Lung Screening Trial (NLST) and seven pilot trials in Europe. 
Recruitment for the NELSON trial recruitment, the only fully powered lung cancer LDCT-
based screening trial in Europe, started in 2003. These five decades of research have now 
provided the lung cancer community with an international framework for the implementation 




Box 1 | Guiding principles for implementation research in lung cancer screening (FIG. 
5).  
 
• Optimize low-dose computed tomography (LDCT)-based lung cancer 
screening by evaluating the cost-effectiveness of existing as well as innovative 
approaches on the basis of risk estimates.  
• Identify the optimal and most cost-effective strategy for inviting high-risk 
individuals (often hard to reach) to participate in population-focused LDCT-
based lung-cancer screening interventions.  
• Estimate the effect of personalized, less-intensive screening regimens with 
longer screening intervals (for example, biennial) relying on health-related risk 
factors detected on baseline LDCT scan and, potentially, on blood-based 
biomarker assays.  
• Explore the effect of integrating effective smoking-cessation interventions 
within lung-cancer screening programmes. 
• Estimate the long-term health outcomes, including benefits and harms, as well 
as cost-effectiveness by incorporating the above recommendations.  
• Develop guidelines and training programmes to facilitate implementation of 
evidence-based, quality-assured LDCT-based lung cancer screening and also 













Table 1 | Lung cancer risk stratification on the basis of baseline and follow-up low-
dose CT screens  
 
Risk categorya Lesions detectedb Recommendation 
Intermediate-to-high risk of 
lung cancer (<1%) 
No baseline nodule 
No new nodule at follow-up 
screening 
Solid baseline nodule  
<100 mm
3
 or <5 mm 
New solid nodule  
<30 mm
3 
or <4 mm 
Consider prolonged 
screening interval of up to 
24 months 
High risk of lung cancer 
(~3%) 
Solid baseline nodule  
100–300 mm
3 
or 5–10 mm 
New solid nodule  
30–200 mm
3 
or 4–8 mm 
Growing solid nodule  
with VDT of 400–600 days 
Subsolid nodule, baseline or 
new, of any size
c
 
Short-term follow-up (3 
months) 
If negative: annual screening 
Very high risk of lung cancer 
(>15%) 
Solid baseline nodule  
>300 mm
3 
or >10 mm 
New solid nodule  
>200 mm
3 
or >8 mm 
Growing solid nodule 
with VDT <400 days 
Subsolid nodule that is 
growing or has an altered 
morphology 
Referral to MDT for workup  
If negative: annual screening 
 
 
MDT, multidisciplinary team; VDT, volume-doubling time. a2-year probability of lung 
cancer, based on largest or fastest-growing nodule. bSize expressed as volume 
(mm3) or longest diameter (mm). cIn case of negative follow-up CT scan (no growth), 









Outcomes in male 
participants 




7.5 years after 
baseline scan 
Screening arm: 
311 lung cancer-related 
deaths among 
15,769 individuals (2.0%) 
No-screening arm: 
337 lung cancer-related 
deaths among 
15,761individuals (2.1%) 
RR 0.92 (95% CI 0.8–
1.08)a 
Screening arm: 






215 lung cancer-related 
deaths among 10,969 
individuals (2.0%) 











733 lung cancer-related 
deaths among 
15,769 individuals (4.6%) 
No-screening arm:755 
lung cancer-related deaths 
among 15,761 individuals 
(4.8%) 
RR 0.97 (95% CI 0.87–
1.07)a  
Screening arm: 





481 lung cancer-related 
deaths among 10,969 
individuals (4.4%) 
RR 0.86 (95% CI 0.75–
0.98)a 
NELSON[10] 
10 years after 
baseline 
Screening arm: 
341 lung cancers detected 
in 6,583 individuals (5.2%) 
156 lung cancer-related 
deaths in 6,583 individuals 
(2.4%) 
No-screening arm: 
304 lung cancers detected 
in 6,612 individuals 
206 lung cancer-related 
deaths in 6,612 individuals 
(3.1%) 
RR 0.76 (0.61–0.94)a 
Screening arm: 
Lung cancers detected: 
NA 
25 lung cancer-related 
deaths in 1,317 
individuals (1.9%) 
No-screening arm: 
36 lung cancer-related 
deaths in 1,277 
individuals (2.8%) 
RR 0.67 (0.38–1.14)a 
 56 
LUSI[6] 
7 years after 
baseline 
Screening arm: 
43 lung cancers detected 
among 1,315 individuals 
(3.3%) 
18 lung cancer-related 
deaths among 1,315 
individuals (1.4%) 
No-screening arm: 
19 lung cancer-related 
deaths among 1,307 
individuals (1.5%) 




20 lung cancers 
detected among 
714 individuals (2.8%) 
2 lung cancer-related 
deaths among 
714 individuals (0.3%) 
No screening arm: 
10 lung cancer-related 
deaths among 716 
individuals (1.4%) 
HR 0.31 (95% CI 0.10–
0.96)a 
 






Supplementary Information  
 
Supplementary Table 1 | Recommendations for implementation of lung cancer 
screening in China. (Reproduced from Cheng et al.121)  
 
 
1. Screening programme coverage to be expanded to underserved areas. Recruitment criteria suggested by 
other countries should be considered. The involvement of international investigators in lung cancer 
screening trials in China should be considered.  
 
 
2. Community-based recruitment may be a more favourable approach in China: utilising face-to-face 
clinical appointments and trustworthy collaborations with local clinics/ organisations.  
 
 
3. To make cohort profiles or study protocols public is suggested. Collaboration between lung cancer 
screening trial groups should be considered. Developing consensus protocols and also the agreement to 




4. In China, consider adapting the entry criteria, i.e. a lower threshold of smoking exposure; consider 
including other risk factors: second-hand smoke, family history of cancer, occupation and indoor/outdoor 
air pollution (the latter requires a harmonised approach).  
 
 
5. Risk-based selection of eligible participants for study entry into lung cancer CT screening programmes 
(e.g. risk prediction modelling) would be advisable.  
 
 
6. The current Chinese risk models (for either individual risk or nodule malignancy prediction) should be 
validated externally, especially in an ongoing lung cancer LDCT screening programme, which could help 
to confirm the efficacy and effectiveness in the real world. Further optimisation may be integrated over 
time, i.e. integration with liquid biomarkers and genetic factors.  
 
 
7. Development of new risk prediction models, specifically for the Chinese population, should be priority, 
utilising optimal data sources.  
 
 
8. Cost-effectiveness analysis of all current CT screening programmes should be undertaken, taking into 
consideration the selection criteria/risk threshold utilised, which would achieve the maximum net benefits 
over harms.  
 
 
9. Evaluation of related parameters involved in the screening programmes requires further research in 




10. Lung cancer screening programmes should be integrated with tobacco control strategies. An a priori 
design and a detailed record on participants’ behaviours/perspectives and study costs including personnel 
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VDT 400-600 days 
LC% ~4% 
Volume ≤400 days 
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Figure 3c Non-calcified subsolid nodule at baseline or new after baseline  
 
 
  Non-calcified subsolid nodule at baseline or new after baseline  
Part-solid, solid component: 
>500mm³ (>10mm) 
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Figure 4 Incremental cost-effectiveness ratios (ICER) per quality-adjusted life-years 
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Table 1 Risk stratification based on the baseline and follow-up CT  
 
Intermediate-high lung 
cancer risk (<1%) 
 
Consider prolonged 
screening interval up to 
24 months 
High lung cancer risk (±3%) 
 
 
Short-term follow-up (3 months), 
if negative: annual screening 
Very high lung cancer 
risk (>15%)  
 
Referral to MDT for 
workup,  
if negative: annual 
screening 
No baseline nodule 
 
Solid baseline nodule  
100 – 300 mm3 or 5 – 10 mm 
Solid baseline nodule  
>300 mm3 or >10 mm 
No new nodule at follow-
up screening 
New solid nodule  
30 – 200 mm3 or 4 – 8 mm 
New solid nodule  
>200 mm3 or >8 mm 
Solid baseline nodule  
<100 mm3 or <5 mm 
Growing solid nodule  
VDT 400-600 days 
Growing solid nodule 
VDT<400 days 
New solid nodule  
<30 mm3 or <4 mm 
Subsolid nodule, baseline or 
new, any size* 
Subsolid nodule showing 
growth or altered 
morphology 
 
Note: Two-year lung cancer probability, based on largest or fastest-growing nodule 
MDT = multidisciplinary team, VDT = volume-doubling time 
*in case of negative follow-up CT (no growth), consider prolonged screening interval 




Table 2 Results of randomized-controlled lung cancer screening trials stratified by 
gender. 
 
Study Men Women 
NLST*96 
 
N (%) 15,769 (59) 10,953 (41) 
LC, N (%) NA NA 
LC mortality, N (%) 311 (2.0) 158 (1.4) 
LC mortality controls 337/15,761 (2.1) 215/10,969 (2.0) 
RR (95% CI) 0.92 (0.8–1.08) 0.73 (0.6–0.9) 
NLST**97 
 
N (%) 15,769 (59) 10,953 (41)  
LC, N (%) NA NA 
LC mortality, N (%) 733 (4.6) 414 (3.8) 
LC mortality controls 755/15,761 (4.8) 481/10,969 (4.4) 
RR (95% CI) 0.97 (0.87–1.07)  0.86 (0.75–0.98) 
NELSON***9 
N (%) 6,583 (83.3) 1,317 (16.7)  
LC, N (%) 341 (5.2) NA 
LC mortality, N (%) 156 (2.4) 25(1.9) 
LC mortality controls 206/6,612 (3.1) 36/1,277 (2.8) 
RR (95% CI) 0.76 (0.61-0.94) 0.67 (0.38-1.14) 
LUSI****5 
N (%) 1,315 (64.8) 714 (35.2) 
LC, N (%) 43 (3.3) 20 (2.8) 
LC mortality, N (%) 18 (1.4) 2 (0.3) 
LC mortality controls 19/1,307 (1.5) 10/716 (1.4) 





Note: numbers in this table were not adjusted for person years 
Abbreviations: CI = confidence interval, HR = hazard ratio, LC = lung cancer, LUSI = 
German Lung cancer Screening Intervention trial, NA = not applicable, NELSON = 
Dutch-Belgian randomized-controlled lung cancer screening trial, NLST = national 
lung cancer screening trial, RR= rate ratio. 
* median follow-up 7.5 years after baseline 
** median follow-up 11.3 years after baseline (incidence), 12.3 years after baseline 
(mortality) 
*** median follow-up 10 years after baseline 










Recommendations for implementation of lung cancer screening in China 
 (Reproduced from Cheng et al.123)  
 
1. Screening programme coverage to be expanded to underserved areas. Recruitment criteria 
suggested by other countries should be considered. The involvement of international 
investigators in lung cancer screening trials in China should be considered.  
 
 
2. Community-based recruitment may be a more favourable approach in China: utilising face-to-
face clinical appointments and trustworthy collaborations with local clinics/ organisations.  
 
 
3. To make cohort profiles or study protocols public is suggested. Collaboration between lung 
cancer screening trial groups should be considered. Developing consensus protocols and also the 
agreement to utilise common databases and minimum datasets would enable pooling of data 
from different trials in China.  
 
 
4. In China, consider adapting the entry criteria, i.e. a lower threshold of smoking exposure; 
consider including other risk factors: second-hand smoke, family history of cancer, occupation 
and indoor/outdoor air pollution (the latter requires a harmonised approach).  
 
 
5. Risk-based selection of eligible participants for study entry into lung cancer CT screening 
programmes (e.g. risk prediction modelling) would be advisable.  
 
 
6. The current Chinese risk models (for either individual risk or nodule malignancy prediction) 
should be validated externally, especially in an ongoing lung cancer LDCT screening 
programme, which could help to confirm the efficacy and effectiveness in the real world. Further 




7. Development of new risk prediction models, specifically for the Chinese population, should be 
priority, utilising optimal data sources.  
 
 
8. Cost-effectiveness analysis of all current CT screening programmes should be undertaken, 
taking into consideration the selection criteria/risk threshold utilised, which would achieve the 
maximum net benefits over harms.  
 
 
9. Evaluation of related parameters involved in the screening programmes requires further 
research in China, e.g. screening interval, screening length, nodule management.  
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10. Lung cancer screening programmes should be integrated with tobacco control strategies. An a 
priori design and a detailed record on participants’ behaviours/perspectives and study costs 
including personnel cost, is required for cost-effectiveness evaluation.  
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